Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Biotechnology

Biocon Limited, together with its subsidiaries, engages in the manufacture and sale of biotechnology products and research services in India, Brazil, Singapore, and internationally. It operates through four segments: Generics, Novel Biologics, Biosimilars, and Research Services. The company offers generic formulations and API products, including anti-diabetics, immunosuppressants, multiple sclerosis, anti-cancer/oncology, and other products; novel biologics products, such as head and neck cancer molecule; novel pipeline products comprising psoriasis molecules; and biosimilars products consisting of insulins, trastuzumab, pegfilgrastim, and bevacizumab. It also provides integrated discovery, development, and manufacturing services to pharmaceutical, biotechnology, animal healthcare, consumer good, and agrochemical companies. Biocon Limited was incorporated in 1978 and is headquartered in Bengaluru, India.

Revenue projections:

Revenue projections for BIOCON
Revenue projections for BIOCON

Investors may react cautiously to news that BIOCON's revenues are forecasted to be lower than last year's. Such declines are likely to have a negative effect on the company's bottom line, which can lead to concerns about profitability and hinder investor confidence in the company's future performance.

Financial Ratios:

currentRatio 1.136000
forwardPE 31.248589
debtToEquity 66.259000
earningsGrowth 1.550000
revenueGrowth 0.128000
grossMargins 0.605710
operatingMargins 0.159770
trailingEps 8.450000
forwardEps 9.920000

Biocon Limited's current ratio of 1.136, indicating that the company can meet its short-term debt obligations with ease. This high liquidity level is a positive sign, as Biocon Limited has enough cash and current assets to handle its immediate liabilities comfortably.
Positive earnings and revenue growth for Biocon Limited suggest that the company is positioned for business expansion. The company's strong financial performance indicates sustained growth, as increasing sales and profits fuel its future success.
BIOCON's forward EPS exceeding its trailing EPS reflects expectations of increased profitability for the current year. This suggests that the company is projected to achieve higher earnings than in the previous financial year, signaling positive growth and improved financial health.

Price projections:

Price projections for BIOCON
Price projections for BIOCON

BIOCON's price has consistently remained near the lower edge of projections, suggesting that it is not fully meeting market expectations. This could indicate a need for improved performance or strategies to boost investor confidence.

Recommendation changes over time:

Recommendations trend for BIOCON
Recommendations trend for BIOCON


Analysts' buy bias for Biocon Limited signals that the stock is considered a favorable investment. This outlook might prompt investors to allocate funds to Biocon Limited, seeing it as a solid and profitable choice to park their money and potentially benefit from the company's long-term growth.